Evotec SE (EVO) Beginning Cash Balance (2021 - 2022)
Evotec SE (EVO) reported Beginning Cash Balance of $784879.9 for Q1 2022, up 53.98% on a YoY basis from $509731.3 in Q1 2021, and up 53.98% sequentially from $509731.3 in Q1 2021.
Evotec SE (EVO) Beginning Cash Balance (2021 - 2022) Analysis & Trends
Evotec SE (EVO) has 2 years of Beginning Cash Balance data on file, last reported at $784879.9 in Q1 2022.
- For the quarter ending Q1 2022, Beginning Cash Balance rose 53.98% year-over-year to $784879.9; the trailing twelve-month figure through Sep 2022 stood at $784879.9 (changed N/A YoY), and the FY2009 full-year result was $76.8 million, changed N/A from the prior year.
- Beginning Cash Balance advanced to $784879.9 in Q1 2022, from $509731.3 in the prior quarter.
- In the past five years, Beginning Cash Balance ranged from a high of $784879.9 in Q1 2022 to a low of $509731.3 in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Evotec SE | 351.60 Mn | 351.08 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 784,879.95 |
| Mar 31, 2022 | 784,879.95 |
| Mar 31, 2021 | 509,731.26 |
| Mar 31, 2021 | 509,731.26 |